1. Leder K, Torresi J, Libman MD. , et al; GeoSentinel Surveillance Network. GeoSentinel surveillance of illness in returned travelers, 2007–2011. Ann Intern Med 2013; 158 (06) 456–468
2. Han MH, Zunt JR. Neurologic aspects of infections in international travelers. Neurologist 2005; 11 (01) 30–44
3. World Health Organization Fact Sheets. Schistosomiasis. 2018 . Available at: http://www.who.int/news-room/fact-sheets/detail/schistosomiasis. Accessed September 9, 2018
4. Carod-Artal FJ. Neurological complications of Schistosoma infection. Trans R Soc Trop Med Hyg 2008; 102 (02) 107–116
5. Walker MD, Zunt JR. Neuroparasitic infections: cestodes, trematodes, and protozoans. Semin Neurol 2005; 25 (03) 262–277
6. Ferrari TC, Moreira PR. Neuroschistosomiasis: clinical symptoms and pathogenesis. Lancet Neurol 2011; 10 (09) 853–864
7. Thakur K, Zunt J. Tropical neuroinfectious diseases. Continuum (Minneap Minn) 2015; 21 (6 Neuroinfectious Disease): 1639–1661
8. World Health Organization Fact Sheets. Trypanosomiasis, human African (sleeping sickness). 2018 . Available at: http://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness) . Accessed September 13, 2018
9. Kennedy PG. Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). Lancet Neurol 2013; 12 (02) 186–194
10. World Health Organization Fact Sheets. Chagas disease (American trypanosomiasis). 2018 . Available at: https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis) . Accessed September 13, 2018
11. Centers for Disease Control and Prevention Resources for Health Professionals. Parasites – American trypanosomiasis (also known as Chagas disease). 2018. Available at: https://www.cdc.gov/parasites/chagas/health\_professionals/index.html. Accessed September 15, 2018
12. Córdova E, Maiolo E, Corti M, Orduña T. Neurological manifestations of Chagas' disease. Neurol Res 2010; 32 (03) 238–244
13. Berkowitz AL, Raibagkar P, Pritt BS, Mateen FJ. Neurologic manifestations of the neglected tropical diseases. J Neurol Sci 2015; 349 (1–2): 20–32
14. Cougo-Pinto PT, Dos Santos BL, Dias FA. , et al. Safety of IV thrombolysis in acute ischemic stroke related to Chagas disease. Neurology 2013; 81 (20) 1773–1775
15. Newton CR, Hien TT, White N. Cerebral malaria. J Neurol Neurosurg Psychiatry 2000; 69 (04) 433–441
16. Shikani HJ, Freeman BD, Lisanti MP, Weiss LM, Tanowitz HB, Desruisseaux MS. Cerebral malaria: we have come a long way. Am J Pathol 2012; 181 (05) 1484–1492
17. Mishra SK, Newton CR. Diagnosis and management of the neurological complications of falciparum malaria. Nat Rev Neurol 2009; 5 (04) 189–198
18. Bill and Melinda Gates Foundation. What we do—malaria: strategy overview. Available at: https://www.gatesfoundation.org/What-We-Do/Global-Health/Malaria. Accessed September 18, 2018
19. World Health Organization Fact Sheets. Meningococcal meningitis. 2018. Available at: http://www.who.int/news-room/fact-sheets/detail/meningococcal-meningitis. Accessed September 20, 2018
20. Serra LC, York LJ, Gamil A, Balmer P, Webber C. A review of meningococcal disease and vaccination recommendations for travelers. Infect Dis Ther 2018; 7 (02) 219–234
21. Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccine. J Adolesc Health 2016; 59 (2, Suppl): S3-S11
22. Stein-Zamir C, Shoob H, Sokolov I, Kunbar A, Abramson N, Zimmerman D. The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J 2014; 33 (07) 777–779
23. Kotilainen P, Jalava J, Meurman O. , et al. Diagnosis of meningococcal meningitis by broad-range bacterial PCR with cerebrospinal fluid. J Clin Microbiol 1998; 36 (08) 2205–2209
24. Nadel S. Treatment of meningococcal disease. J Adolesc Health 2016; 59 (2, Suppl): S21-S28
25. Xu G, Walker DH, Jupiter D, Melby PC, Arcari CM. A review of the global epidemiology of scrub typhus. PLoS Negl Trop Dis 2017; 11 (11) e0006062
26. Weitzel T, Dittrich S, López J. , et al. Endemic scrub typhus in South America. N Engl J Med 2016; 375 (10) 954–961
27. Rapsang AG, Bhattacharyya P. Scrub typhus. Indian J Anaesth 2013; 57 (02) 127–134
28. Mahajan SK, Mahajan SK. Neuropsychiatric manifestations of scrub typhus. J Neurosci Rural Pract 2017; 8 (03) 421–426
29. Pai H, Sohn S, Seong Y, Kee S, Chang WH, Choe KW. Central nervous system involvement in patients with scrub typhus. Clin Infect Dis 1997; 24 (03) 436–440
30. El Sayed I, Liu Q, Wee I, Hine P. Antibiotics for treating scrub typhus. Cochrane Database Syst Rev 2018; 9: CD002150
31. World Health Organization. Zoonoses. 2018 . Available at: http://www.who.int/zoonoses/diseases/lerg/en/index2.html. Accessed September 23, 2018
32. Levett PN. Leptospirosis. Clin Microbiol Rev 2001; 14 (02) 296–326
33. Gancheva GI, Kostadinova MA, Kostadinova PI. Involvement of central nervous system in leptospirosis. J Biomed Clin Res. 2009; 2 (02) 109–114
34. Panicker JN, Mammachan R, Jayakumar RV. Primary neuroleptospirosis. Postgrad Med J 2001; 77 (911) 589–590
35. Chiappe-Gonzalez A, Ticona-Huaroto C, Hoerster V. , et al. Primary neuroleptospirosis: a case report and literature review. Infect Dis Clin Pract 2017; 25: 329–331
36. Wilson MR, Naccache SN, Samayoa E. , et al. Actionable diagnosis of neuroleptospirosis by next-generation sequencing. N Engl J Med 2014; 370 (25) 2408–2417
37. de Vries SG, Visser BJ, Stoney RJ. , et al; For The GeoSentinel Surveillance Network. Leptospirosis among returned travelers: a GeoSentinel survey and multicenter analysis 1997–2016. Am J Trop Med Hyg 2018; 99 (01) 127–135
38. Smythe LD, Wuthiekanun V, Chierakul W. , et al. The microscopic agglutination test (MAT) is an unreliable predictor of infecting Leptospira serovar in Thailand. Am J Trop Med Hyg 2009; 81 (04) 695–697
39. Brett-Major DM, Coldren R. Antibiotics for leptospirosis. Cochrane Database Syst Rev 2012; 2 (02) CD008264
40. Takafuji ET, Kirkpatrick JW, Miller RN. , et al. An efficacy trial of doxycycline chemoprophylaxis against leptospirosis. N Engl J Med 1984; 310 (08) 497–500
41. Zhao S, Cheng Y, Liao Y, Zhang Z, Yin X, Shi S. Treatment efficacy and risk factors or neurobrucellosis. Med Sci Monit 2016; 22: 1005–1012
42. Guven T, Ugurlu K, Ergonul O. , et al. Neurobrucellosis: clinical and diagnostic features. Clin Infect Dis 2013; 56 (10) 1407–1412
43. Centers for Disease Control and Prevention. Brucellosis Reference Guide: exposures, testing, and prevention. 2017. Available at: https://www.cdc.gov/brucellosis/pdf/brucellosi-reference-guide.pdf. Accessed September 26, 2018
44. Corbel MJ. Brucellosis in humans and animals. 2006 . Available at: https://www.who.int/csr/resources/publications/Brucellosis.pdf. Accessed April 4, 2019
45. Gul HC, Erdem H, Bek S. Overview of neurobrucellosis: a pooled analysis of 187 cases. Int J Infect Dis 2009; 13 (06) e339-e343
46. Al Dahouk S, Tomaso H, Nöckler K, Neubauer H, Frangoulidis D. Laboratory-based diagnosis of brucellosis--a review of the literature. Part II: serological tests for brucellosis. Clin Lab 2003; 49 (11–12): 577–589
47. Erdem H, Ulu-Kilic A, Kilic S. , et al. Efficacy and tolerability of antibiotic combinations in neurobrucellosis: results of the Istanbul study. Antimicrob Agents Chemother 2012; 56 (03) 1523–1528
48. Pappas G, Akritidis N, Christou L. Treatment of neurobrucellosis: what is known and what remains to be answered. Expert Rev Anti Infect Ther 2007; 5 (06) 983–990
49. Mehta R, Soares CN, Medialdea-Carrera R. , et al. The spectrum of neurological disease associated with Zika and chikungunya viruses in adults in Rio de Janeiro, Brazil: A case series. PLoS Negl Trop Dis 2018; 12 (02) e0006212
50. Calvet GA, Santos FB, Sequeira PC. Zika virus infection: epidemiology, clinical manifestations and diagnosis. Curr Opin Infect Dis 2016; 29 (05) 459–466
51. Chen TH, Staples E, Fisher M. CDC Yellow Book 2018: Health Information for International Travel. Chapter 3: Zika. February 2018. Available at: https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/zika. Accessed October 26, 2018
52. Parra B, Lizarazo J, Jiménez-Arango JA. , et al. Guillain-Barré syndrome associated with zika virus infection in Colombia. N Engl J Med 2016; 375 (16) 1513–1523
53. Rabe IB, Staples JE, Villanueva J. , et al; MTS. Interim guidance for interpretation of Zika virus antibody test results. MMWR Morb Mortal Wkly Rep 2016; 65 (21) 543–546
54. do Rosário MS, de Jesus PA, Vasilakis N. , et al. Guillain-Barré syndrome after zika virus infection in Brazil. Am J Trop Med Hyg 2016; 95 (05) 1157–1160
55. Chancey C, Grinev A, Volkova E, Rios M. The global ecology and epidemiology of West Nile virus. BioMed Res Int 2015; 2015: 376230
56. Hart Jr J, Tillman G, Kraut MA. , et al; NIAID Collaborative Antiviral Study Group West Nile Virus 210 Protocol Team. West Nile virus neuroinvasive disease: neurological manifestations and prospective longitudinal outcomes. BMC Infect Dis 2014; 14: 248
57. World Health Organization Fact Sheets. West Nile virus. 2018 . Available at: http://www.who.int/news-room/fact-sheets/detail/west-nile-virus. Accessed October 1, 2018
58. Centers for Disease Control and Prevention. West Nile virus: information for healthcare providers. 2018. Available at: https://www.cdc.gov/westnile/healthcareproviders/index.html. Accessed October 1, 2018
59. Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin Infect Dis 2007; 44 (12) 1617–1624
60. World Health Organization Fact Sheets. Japanese encephalitis. 2015 . Available at: http://www.who.int/news-room/fact-sheets/detail/japanese-encephalitis. Accessed October 1, 2018
61. Hills SL, Rabe IB, Fischer M. CDC Yellow Book 2018: Health Information for International Travel. Chapter 3: Japanese encephalitis. February 2018. Available at: https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/japanese-encephalitis. Accessed October 6, 2018
62. Knust B, Choi M. CDC Yellow Book 2018: Health Information for International Travel. Chapter 3: Viral hemorrhagic fevers. February 2018. Available at: https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/viral-hemorrhagic-fevers. Accessed October 25, 2018
63. Boushab BM, Fall-Malick FZ, Ould Baba SE. , et al. Severe human illness caused by rift valley fever virus in Mauritania 2015. Open Forum Infect Dis 2016; 3 (04) ofw200
64. Okokhere PO, Rafiu MO, Bankole IA. Central nervous system disease associated with major viral haemorrhagic fever viruses of public health importance: challenges in patient diagnosis, evaluation, and management in resource-limited settings. EMJ Neurol 2017; 5 (01) 73–81
65. Abreu-Mota T, Hagen KR, Cooper K. , et al. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever. Nat Commun 2018; 9 (01) 4223
66. Henao-Restrepo AM, Camacho A, Longini IM. , et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 2017; 389 (10068): 505–518
67. Ambrosio A, Saavedra M, Mariani M, Gamboa G, Maiza A. Argentine hemorrhagic fever vaccines. Hum Vaccin 2011; 7 (06) 694–700
68. Faburay B, LaBeaud AD, McVey DS, Wilson WC, Richt JA. Current status of rift valley fever vaccine development. Vaccines (Basel) 2017; 5 (03) E29
69. Singh R, Singh KP, Cherian S. , et al. Rabies - epidemiology, pathogenesis, public health concerns and advances in diagnosis and control: a comprehensive review. Vet Q 2017; 37 (01) 212–251
70. Petersen BW, Wallace RM, Shlim DR. CDC Yellow Book 2018: Health Information for International Travel. Chapter 3: Rabies. February 2018. Available at: https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/rabies. Accessed October 15, 2018
71. World Health Organization Fact Sheets. Rift Valley fever. 2018. Available at: http://www.who.int/news-room/fact-sheets/detail/rift-valley-fever. Accessed October 10, 2018
72. Alexander JP, Patel M, Wassilak SGF. CDC Yellow Book 2018: Health Information for International Travel. Chapter 3: Poliomyelitis. February 2018. Available at: https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/poliomyelitis. Accessed October 26, 2018
73. Gonzalez H, Olsson T, Borg K. Management of postpolio syndrome. Lancet Neurol 2010; 9 (06) 634–642
74. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 2017; 16 (11) 877–897